Canaccord analyst Bill Maughan lowered the firm’s price target on Fate Therapeutics to $9 from $11 and keeps a Buy rating on the shares. The firm sees the positive data from the B-cell lymphoma program as a proof-of-concept and positive readthrough for the application of ‘819 in autoimmune indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Advances in Autoimmune and Cancer Therapies
- Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
- FATE Earnings this Week: How Will it Perform?
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting